Sequencing With Osimertinib in EGFR-Mutated NSCLC

preview_player
Показать описание
Considerations for interpreting data related to the use of osimertinib for the treatment of EGFR-positive non–small cell lung cancer and insight regarding strategies for sequencing therapy.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Sequencing With Osimertinib 0:02:50

Sequencing With Osimertinib in EGFR-Mutated NSCLC

Sequencing With Osimertinib 0:03:57

Sequencing With Osimertinib in EGFR-Positive NSCLC

Sequencing of Therapies 0:03:24

Sequencing of Therapies in EGFR-Mutant NSCLC

EGFR-Mutant NSCLC: Selecting 0:03:27

EGFR-Mutant NSCLC: Selecting Patients for Osimertinib

Dr. Goldberg on 0:02:00

Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLC

Sequential treatment with 0:06:28

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC

Dr. Bazhenova on 0:01:58

Dr. Bazhenova on Sequencing Beyond Progression in EGFR-Mutant NSCLC

Case 4: EGFR 0:05:24

Case 4: EGFR Mutation Analysis Post-Osimertinib

Patient Selection for 0:04:56

Patient Selection for Osimertinib; Thoughts on Sequencing

Sequential afatinib and 0:06:43

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

Case 2: Osimertinib 0:03:09

Case 2: Osimertinib in EGFR-Mutated Lung Cancer

EGFR TKI Sequencing 0:05:45

EGFR TKI Sequencing

Osimertinib for EGFR 0:03:59

Osimertinib for EGFR T790M Resistance Mutations in NSCLC

Advancing Care for 0:53:55

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine Strategies

Resistance to Osimertinib 0:01:53

Resistance to Osimertinib in EGFR-Mutated NSCLC

EGFR Mutated NSCLC 0:03:20

EGFR Mutated NSCLC Disease Progression on Osimertinib - 2022 Program: Targeted Therapies Forum

Detectability of uncommon 0:01:21

Detectability of uncommon EGFR mutations in NSCLC: NGS versus PCR

Global Perspectives on 0:08:55

Global Perspectives on Use of Osimertinib in EGFR+ NSCLC

Treating With Osimertinib 0:04:04

Treating With Osimertinib in EGFR-Mutated NSCLC

Investigating Osimertinib for 0:00:48

Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer

Molecular testing in 0:01:04

Molecular testing in EGFR mutant driven NSCLC

Dr. Zhu on 0:02:23

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC

Comment: Front-line osimertinib 0:01:36

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...

Dr. Fidler Discusses 0:00:42

Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer